Literature DB >> 11293906

Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma.

E Schlette1, C Bueso-Ramos, F Giles, A Glassman, K Hayes, L J Medeiros.   

Abstract

We studied 20 cases of mature B-cell leukemia with more than 55% prolymphocytes in peripheral blood or bone marrow, fulfilling the French-American-British criteria for B-cell prolymphocytic leukemia (PLL). Cases segregated into 3 groups: de novo PLL, 6; PLL occurring in patients with a previous well-established diagnosis of chronic lymphocytic leukemia (PLL-HxCLL), 10; and t(11;14)(q13;q32)-positive neoplasms, 4. All cases expressed monotypic immunoglobulin light chain, and most were positive for CD5. All t(11;14)-positive neoplasms were CD23- and uniquely positive for cyclin D1. Cytogenetic abnormalities were present in 19; in all 19, the karyotype was complex, indicating clonal evolution and genomic instability. The most frequent cytogenetic abnormality in de novo PLL involved chromosome 7 in 4 cases. Trisomy 12 or add(12p) was present in 4 cases of PLL-HxCLL. We conclude that mature B-cell leukemias with more than 55% prolymphocytes are a heterogeneous group that includes t(11;14)-positive neoplasms, which we suggest are best classified as mantle cell lymphoma. We also suggest that prolymphocytic morphologic features are a common end-stage of transformation for several B-cell neoplasms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11293906     DOI: 10.1309/PPK0-TJUK-1UAR-3194

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia.

Authors:  Aruna Gavini; Gladys H Telang; Adam J Olszewski
Journal:  Int J Hematol       Date:  2012-03       Impact factor: 2.490

Review 2.  Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.

Authors:  Aude Collignon; Anne Wanquet; Elsa Maitre; Edouard Cornet; Xavier Troussard; Thérèse Aurran-Schleinitz
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

3.  B-cell lymphomas with discordance between pathological features and clinical behavior.

Authors:  Laurence de Leval; Christiane Copie-Bergman; Andreas Rosenwald; Lisa Rimsza; Stefania Pittaluga; Bettina Bisig; Stefan Dirnhofer; Fabio Facchetti; Stefano Pileri; Falko Fend; Andrew Wotherspoon
Journal:  Virchows Arch       Date:  2017-06-01       Impact factor: 4.064

Review 4.  Prolymphocytic leukemia.

Authors:  Ahmed Absi; Eric Hsi; Matt Kalaycio
Journal:  Curr Treat Options Oncol       Date:  2005-05

5.  Co-occurrence of JAK2 V617F-mutated essential thrombocythemia and chronic lymphocytic leukemia harboring der(8;17)(q10;q10).

Authors:  Masahiro Manabe; Nao Tanizawa; Satoru Nanno; Yuuji Hagiwara; Reiko Asada; Ki-Ryang Koh
Journal:  Cancer Rep (Hoboken)       Date:  2022-06-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.